We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

160 hedge funds and large institutions have $1.5B invested in Epizyme, Inc in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 67 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,585% more call options, than puts

Call options by funds: $59.2M | Put options by funds: $3.52M

86% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 36

86% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 21

12% more funds holding

Funds holding: 143160 (+17)

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

2% more capital invested

Capital invested by funds: $1.47B → $1.5B (+$29.2M)

Holders
160
Holders Change
+17
Holders Change %
+11.89%
% of All Funds
3.28%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.21%
New
39
Increased
67
Reduced
36
Closed
21
Calls
$59.2M
Puts
$3.52M
Net Calls
+$55.7M
Net Calls Change
+$12.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$242M +$26M +1,491,256 +11%
RM
2
RP Management
New York
$147M
RG
3
Redmile Group
California
$136M -$4.94M -282,870 -3%
BlackRock
4
BlackRock
New York
$122M +$13.4M +770,240 +11%
Vanguard Group
5
Vanguard Group
Pennsylvania
$116M +$3.91M +223,768 +3%
PAI
6
Palo Alto Investors
California
$88.5M -$666K -38,127 -0.7%
State Street
7
State Street
Massachusetts
$61.4M +$23.2M +1,326,805 +53%
MB
8
MPM BioImpact
Massachusetts
$37.4M
Victory Capital Management
9
Victory Capital Management
Texas
$36.9M -$36M -2,060,058 -47%
RSCM
10
Rock Springs Capital Management
Maryland
$33.8M +$2.6M +149,084 +8%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$32.6M +$11.3M +645,097 +47%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$32.3M -$30.2K -1,728 -0.1%
Janus Henderson Group
13
Janus Henderson Group
United Kingdom
$32M +$810K +46,404 +2%
AG
14
Artal Group
Luxembourg
$30.1M -$7.42M -425,000 -18%
Loomis, Sayles & Company
15
Loomis, Sayles & Company
Massachusetts
$22.3M +$2.1M +120,452 +10%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$20.9M +$2.4M +137,451 +12%
Norges Bank
17
Norges Bank
Norway
$20.8M -$854K -48,918 -4%
Northern Trust
18
Northern Trust
Illinois
$17.8M +$2.47M +141,778 +15%
FCMI
19
Foresite Capital Management III
California
$16M +$4.97M +284,466 +40%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$15.6M -$1.26M -72,023 -7%
BCM
21
Burrage Capital Management
Massachusetts
$14.3M -$42.3K -2,421 -0.3%
FCMI
22
Foresite Capital Management II
California
$13.8M +$8.42M +482,421 +127%
Invesco
23
Invesco
Georgia
$13.7M +$3.75M +214,662 +34%
Morgan Stanley
24
Morgan Stanley
New York
$11M +$10.4M +594,874 +649%
Goldman Sachs
25
Goldman Sachs
New York
$10.1M +$3.3M +188,840 +43%

EPZM Hedge Fund Activity: Q2 2020 in Review

160 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2020, worth a combined $1.5B — up 2% from $1.47B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new EPZM positions and 21 closed out — a net gain of 18 holders — while 67 added to existing stakes and 36 trimmed.

The largest buyer was Primecap Management, adding an estimated $26M. The largest seller was NEA Management Company, exiting entirely with an estimated $67.9M sold.

  • 160 institutional investors held Epizyme, Inc (EPZM) as of Q2 2020, up from 143 in Q1 2020.
  • Funds reported $1.5B of Epizyme, Inc stock for Q2 2020, up 2% quarter-over-quarter.
  • 39 funds opened new Epizyme, Inc positions in Q2 2020 and 21 closed out, a net change of +18 holders.
  • The largest Epizyme, Inc buyer in Q2 2020 was Primecap Management, an estimated $26M added.
  • The largest Epizyme, Inc seller in Q2 2020 was NEA Management Company, an estimated $67.9M sold.

Based on aggregated 13F filings for Q2 2020.